|drug693||Cardiopulmonary resuscitation Wiki||0.50|
|drug1038||Direct laryngoscopy Wiki||0.50|
|drug3139||Standard of Care (Intravenous access) Wiki||0.50|
There are 4 clinical trials
The safety and efficacy of a laryngoscopy as a primary intubation tool in urgent endotracheal intubation of cardiac arrest patients with suspected/confirmed COVID-19 has not been well-described in the literature. This study will answer whether using a Vie Scope laryngoscope will impact on the efficacy and safety of intubation compared with a traditional direct laryngoscopy.
Description: Definition of failed intubation: Time to intubation is longer than 120 seconds or wrong placement of endotracheal tube (For example : Esophageal intubation etc.)Measure: Intubation success rate during at the first laryngoscopy Time: 10 min
Description: Intubation difficulty assessed by Intubation difficulty Scale scoreMeasure: Intubation difficulty Scale score Time: 10 min
Description: Complications related to tracheal intubation during advanced Cardiopulmonary Resuscitation (CPR): failure, esophageal intubation, mainstem intubation, vomiting, pulmonary aspiration, dental trauma, extubationMeasure: Complications related to tracheal intubation Time: 10 min
Description: Time to completion of tracheal intubation (TI) procedure measured from the instant that the laryngoscope blade touches the patient to the moment that the tracheal tube cuff is inflatedMeasure: Time to completion of tracheal intubation (TI) procedure Time: 10 min
Description: Duration of the interruption of chest compression during ETI procedureMeasure: Duration of the interruption of chest compression during ETI procedure Time: 10 min
Description: We will record the best laryngeal View during intubation. We will record according to the Cormack-Lehane Grade system.Measure: Laryngeal View during intubation Time: 10 min
Description: self-reported percentage of glottis opening (POGO) scoreMeasure: POGO score Time: 10 min
The current COVID-19 pandemic, this is especially since the transmission of SARS-CoV-2 is thought to occur mainly through respiratory droplets generated by coughing and sneezing, by direct contact with contaminated surfaces and because in a large number of patients COVID-19 disease may be asymptomatic. As recommended by the CDC medical personnel should be equipped with full personal protective equipment (PPE) for AGP in contact with suspected/confirmed COVID-19 patient. Therefore, it is reasonable to search for the most effective methods of intravascular access in those conditions.
Description: successful placement of intravascular deviceMeasure: Success rate of first intravascular access attempt Time: 1 day
Description: time to successful accessMeasure: time to successful access Time: 1 day
Description: number of attempts to successful accessMeasure: number of attempts to successful access Time: 1 day
Description: time to therapy including but not limited to time to fluids, antibiotics, and antiarrythmicsMeasure: time to infusion Time: 1 day
Description: complication ratesMeasure: complication rates Time: 1 day
Description: the rate of survival to hospital admissionMeasure: ROSC Time: 1 day
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for the novel coronavirus disease 2019 (COVID-19) pandemic. Among COVID-19 complications, in-hospital cardiac arrest (IHCA) was reported with a very poor outcome in a retrospective single-center study (0,7% of 30 days survival with good neurological outcome among IHCA patients with a resuscitation attempt), related to its natural course and management. The incidence of unexpected in-ICU cardiac arrest (ICUCA) due to COVID-19 is still unknown. Additionally, outcome of COVID-19 patients admitted in ICU for an out-of-hospital cardiac arrest (OHCA) is also undescribed. The objective this study is : - to report the incidence of ICUCA among patients hospitalized in French ICU for COVID-19. - to report morbidity and mortality among COVID-19 patients admitted alive in ICU for an OHCA or an IHCA. The secondary objective is to assess outcome and identify risk factors of ICUCA occurrence among patients admitted for COVID-19.
Description: Percentage of unexpected in-intensive care unit cardiac arrest among COVID-19 patients admitted to intensive care unitMeasure: Incidence of unexpected cardiac arrest Time: 7 months
Description: Diabetes, hypertension, smoking, dyslipidemia, coronary artery disease, chronic respiratory insufficiency, chronic heart failure, chronic renal insufficiency, chronic hepatic insufficiency, chronic neurological disease, cancer, malignant hemopathy. Charlson score's minimum and maximum values are 0 and 40 respectively, the lowest score corresponds to a better outcome.Measure: Charlson score Time: 7 months
Description: Respiratory failure, neurological impairment, circulatory failure, hepatic failure, haematological failure, renal failure. Sofa score's minimum and maximum values are 0 and 24, the lowest score corresponds to a better outcomeMeasure: Organ failure score at ICU admission and/or before unexpected in-ICU cardiac arrest Time: 7 months
Description: Cardiac origin; Respiratory origin; Metabolic origin; unknown originMeasure: Etiology retained to explain cardiac arrest occurrence Time: 7 months
Description: 0 - no symptoms at all - no significant disability despite symptoms; able to carry out all usual duties and activities - Slight disability; unable to carry out all previous activities, but able to look after own affairs without assistance - Moderate disability; requiring some help, but able to walk without assistance - Moderately severe disability; unable to walk and attend to bodily needs without assistance - Severe disability; bedridden, incontinent and requiring constant nursing care and attention - DeadMeasure: Modified Rankin score (mRS) at ICU discharge, at hospital discharge and at 3 months Time: 3 months
COVID-19, which emerged in China in December 2019, has become a pandemic with its spread to many countries of the world. Although it is suggested that hospital admissions are reduced due to some reasons such as trauma, during COVID-19 pandemic, it is controversial whether in-hospital mortality rates changed. Therefore this multi-centered study aimed to determine how in-hospital mortality effected during the pandemic period according to the specific patient groups.
Description: During the pandemic (March-July), deaths occurred in hospital will be evaluated.Measure: In-hospital mortality Time: 4 months
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports